Żelazny, P. et al. 2022. Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF). Journal of Education, Health and Sport. 12, 9 (Sep. 2022), 583–588. DOI:https://doi.org/10.12775/JEHS.2022.12.09.068.